NCT00111579已完成2 期
A Prospective, Randomized, Open-Label Study to Evaluate the Immune Responses of Trivalent Cold-Adapted Influenza Vaccine (CAIV-T) Compared With Trivalent Inactivated Vaccine (TIV) in Children 6 to <36 Months of Age
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 52
- 试验地点
- 10
- 主要终点
- The following immunogenicity endpoints: The strain-specific HAI seroconversion rates (≥ 4-fold increase) among baseline seronegative participants (HAI titer ≤ 1:4), by dose number
研究概览
简要总结
The purpose of this study is to describe the level of serum antibody conferred by CAIV-T and TIV against homotypic and heterotypic influenza virus strains.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 6 Months 至 36 Months（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male or Female
- •Ages 6 to but less than 36 months (reached their 6th month but have not yet reached their 3rd birthday) at the time of randomization
- •Written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization (if applicable) obtained from the participant's parent/legal representative
- •Ability of the parent/legal representative to understand and comply with the requirements of the study
- •Parent/legal representative available by telephone
- •Ability to complete follow-up period of 180 days after final study vaccination, as required by the protocol
排除标准
- •History of hypersensitivity to any component of CAIV-T or TIV, including egg or egg products, monosodium glutamate, porcine gelatin or thimerosal
- •History of hypersensitivity to gentamicin
- •Any known immunosuppressive condition or immune deficiency disease (including HIV infection), or ongoing receipt of any immunosuppressive therapy
- •Household contact who is immunocompromised (participants should also avoid close contact with immunocompromised individuals for at least 21 days after each study vaccination)
- •History of Guillain-Barre syndrome
- •Medically diagnosed wheezing, bronchodilator use, or steroid use (systemic or inhaled), by parent/legal representative report or chart review, within the 42 days prior to randomization (i.e., children with recent persistent asthma are excluded); or history of severe persistent asthma, according to the criteria described in the National Asthma Education and Prevention Program (NAEPP) Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma - Update on Selected Topics 2002
- •Acute febrile (not greater than 100.0 degrees F oral or equivalent) and/or clinically significant respiratory illness (e.g., cough or sore throat) within 72 hours prior to either study vaccination
- •Use of aspirin or aspirin-containing products within 30 days prior to randomization, or expected use through 180 days after final study vaccination
- •Receipt of any prior influenza vaccine
- •Use of anti-influenza medications (including amantadine, rimantadine, oseltamivir, and zanamivir) within 14 days prior to randomization, or expected use through 180 days after final study vaccination
- •Administration of any live virus vaccine within 30 days prior to randomization, or expected receipt through 30 days after final study vaccination
- •Administration of any inactivated (i.e., non-live) vaccine within 14 days prior to randomization, or expected receipt within 14 days before, or 14 days after, either study vaccination
- •Receipt of any investigational agent within 30 days prior to randomization, or expected receipt through 180 days after final study vaccination (use of licensed agents for indications not listed in the package insert is permitted)
- •Receipt of any blood product within 90 days prior to randomization, or expected receipt through 180 days after final study vaccination
- •Family member or household contact who is an employee of the research center or otherwise involved with the conduct of the study
- •Any condition that, in the opinion of the investigator, would interfere with evaluation of the vaccine or interpretation of the study results
结局指标
主要结局
The following immunogenicity endpoints: The strain-specific HAI seroconversion rates (≥ 4-fold increase) among baseline seronegative participants (HAI titer ≤ 1:4), by dose number
时间窗: Day 28 post final vaccination
The proportion of participants achieving ≥ 4-fold increase in strain-specific HAI titer from baseline in all participants regardless of baseline serostatus, by dose number
时间窗: Day 28 post final vaccination
次要结局
- Safety endpoints include: AEs SAEs and significant new medical conditions for all participants(Day 28 post vaccination)
研究者
研究点 (10)
Loading locations...
相似试验
已完成
1 期
Safety and Immunogenicity of Different Formulations of an Adjuvanted, Trivalent Subunit Influenza Vaccine in Elderly Subjects 65 Years of Age and AboveInfluenzaNCT02126761Seqirus196
已完成
2 期
Sanofi H1N1 + TIV - Adults and ElderlyInfluenzaNCT00943878National Institute of Allergy and Infectious Diseases (NIAID)805
已完成
2 期
Sanofi Pasteur, TIV + H1N1, Pediatric PopulationInfluenzaNCT00943202National Institute of Allergy and Infectious Diseases (NIAID)531
已完成
3 期
Trial to Compare the Safety,Tolerability and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Influenza Virus Vaccine, Trivalent, Inactivated (TIV) in ChildrenRespiratory Tract InfectionsNCT00192205MedImmune LLC2,200
已完成
2 期
Extension Study of H01_04TP to Evaluate the Booster Response Induced by Vi-CRM197 in AdultsTyphoid FeverNCT01438996Novartis51